Pluri
Jingyi Song is a seasoned business development analyst with extensive experience across various industries, including biotechnology, data analytics, and international trade. Currently at Pluri since May 2021, Jingyi has contributed to developing competitive databases and financial models supporting allogeneic cell therapy and immunotherapy. Previous roles include data analyst at Signals Analytics and business analyst at Qlarium Technologies, where Jingyi built risk assessment systems. Jingyi also co-founded Shawoom and held managerial positions at Velocity Consulting and PepsiCo China, where responsibilities encompassed business intelligence, account management, and sales analysis. Jingyi holds a Bachelor's degree in Business Administration from Shanghai Normal University.
Pluri
3 followers
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.